drugset / Trial / NCT02064439

Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)

NCT02064439

Phase 3 Completed 3365 enrolled Bayer Janssen Scientific Affairs, LLC · collab
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This is a multicenter, randomized, double-blind, event-driven, superiority study for efficacy. Patients with confirmed symptomatic DVT (Deep Vein Thrombosis) or PE (Pulmonary embolism) who completed 6 or 12 months of treatment of anticoagulation are eligible for this trial

Timeline

Start
2014-03-05
Primary completion
2016-09-22
Completion
2016-11-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Acetylsalicylic Acid Unknown 100 mg
Subject Rivaroxaban Other / unclassified 10 mg
Subject Rivaroxaban Other / unclassified 20 mg